
Semaglutide Lowered Heart Filling Pressures in a Small Obesity-Related Heart Failure Trial, Plus New Tirzepatide MRI Data From SUMMIT
Notas do episódio
Two new sets of heart-failure data on GLP-1-based drugs were presented at the American Heart Association's Scientific Sessions 2026 in Chicago on November 8, 2026. In CAMEO-SEMA, a Mayo Clinic-led, double-blind trial published in Nature Medicine, 81 adults with obesity and heart failure with preserved ejection fraction (HFpEF) were randomized to semaglutide 2.4 mg weekly or placebo for 52 weeks. Pressure inside the left side of the heart during low-intensity exercise, measured by catheter, fell by an average of 9.8 mmHg on semaglutide and rose 0.9 mmHg on placebo (a difference of 10.6 mmHg), resting pressure also fell more, and 53.7% of people on semaglutide versus 7.4% on placebo had normal pressures at rest and during exercise at 52 weeks. A 49-person MRI substudy reported improvements in left atrial function and heart filling. We also cover a new three-dimensional MRI analysis from Lilly's tirzepatide SUMMIT trial, which found that left atrial volume and right ventricular mass decreased compared with placebo. These are small studies of pressure and imaging measures, not hospitalizations or deaths, the reports we have do not include side-effect data, and the two drugs were not compared with each other.
Sources
- Nature Medicine (Nov 8, 2026), Borlaug et al., hemodynamic effects of semaglutide in HFpEF and obesity (CAMEO-SEMA): nature.com
- Nature Medicine (Nov 8, 2026), Ghanbari et al., CAMEO-SEMA cardiac MRI substudy: nature.com
- ClinicalTrials.gov, NCT05371496 (CAMEO-SEMA): clinicaltrials.gov
- Radcliffe Cardiology (Nov 8, 2026), SUMMIT: tirzepatide and cardiac remodelling in HFpEF, interview with Dr. Milton Packer: radcliffeckm.com
- American College of Cardiology (Nov 16, 2024), original SUMMIT results: acc.org
- American Heart Association, Scientific Sessions 2026 late-breaking science program: professional.heart.org
Cover: original code-generated illustration (no photo).
This episode is for information only and is not medical advice. Always talk to your doctor before starting, stopping, or changing any medication.
Visit glp1newspaper.com for today's stories and free email alerts.
Todos os episódios de GLP-1 Newspaper: Daily Ozempic, Zepbound & Weight-Loss Drug News